What Is MitoPrime? NAD+/MOTS-c/5-Amino-1MQ Blend (2026)

MitoPrime is a research blend of NAD+, MOTS-c, and 5-Amino-1MQ in one 120mg vial. A research guide to the components, mechanism, dosage, and safety.

MitoPrime is a three-component research blend that packs NAD+ (100 mg), MOTS-c (10 mg), and 5-Amino-1MQ (10 mg) into a single 120 mg lyophilized vial. It is sold for laboratory research, and each ingredient targets the same broad goal from a different angle: cellular energy, metabolism, and the biology of aging. Two of the three are not classical peptides at all, which is the first thing worth clearing up.

This guide breaks down what sits inside the vial, how the three compounds are thought to work together, what the published research actually shows for each one, and where the honest gaps are. There is no human trial of this exact combination, so the evidence here is built from studies on the individual components, most of it preclinical.

What's inside a MitoPrime vial

A standard MitoPrime vial holds 120 mg of total lyophilized powder, split three ways. The ratio is heavily weighted toward NAD+, with the two metabolic compounds dosed at a tenth of that each.

Only MOTS-c is a true peptide. NAD+ is a coenzyme, and 5-Amino-1MQ is a small molecule. Vendors group all three under the "peptide blend" label because that is the market they sell into, not because the chemistry agrees. Keep that in mind whenever you see the trio marketed as a peptide stack.

How the three components are meant to work together

The logic behind the blend is a NAD+ story. NAD+ is the shared currency that ties the three ingredients into one thesis, and each compound touches that pool in a different place.

Start with the raw material. NAD+ itself is the coenzyme that mitochondria burn through to make ATP and that sirtuins and DNA-repair enzymes consume as fuel. Levels of it fall as we age. Adding NAD+ directly is the most literal way to top up the tank.

Now the enzyme problem. An enzyme called NNMT (nicotinamide N-methyltransferase) drains the NAD+ salvage pathway by methylating nicotinamide, one of NAD+'s precursors. When NNMT runs hot, less precursor gets recycled back into NAD+. 5-Amino-1MQ blocks NNMT, which in preclinical models frees up more of that precursor and lifts NAD+ inside fat tissue. So one ingredient supplies NAD+, and another is thought to stop the body from wasting it.

MOTS-c is the third lever. It is encoded inside mitochondrial DNA and activates AMPK, the cell's master energy sensor, pushing tissue toward burning fuel rather than storing it. Its own activity is sensitive to the cell's NAD+ and metabolic state.

Put the three together and the pitch is a loop: supply NAD+, protect NAD+, then flip on the pathways that spend it productively. It is a coherent rationale. It is also, at the blend level, a hypothesis. No study has tested these three together in animals or humans, so the synergy is reasoned from mechanism, not measured.

NAD+ (100 mg): the coenzyme doing the heavy lifting

NAD+ (nicotinamide adenine dinucleotide) is not a peptide and not a drug. It is a coenzyme your cells already make from vitamin B3, and it is central to two things: shuttling electrons through energy metabolism, and serving as a required cofactor for sirtuins, PARPs, and CD38.

The reason it shows up in longevity blends is decline. A 2021 review in Nature Reviews Molecular Cell Biology describes a gradual drop in tissue and cellular NAD+ across aging in rodents and humans, and links that fall to metabolic disease, cognitive decline, and sarcopenia [1]. Restoring NAD+ has become one of the more active areas in aging research.

One honest caveat belongs here. Injecting or infusing NAD+ directly is different from taking a precursor like NR or NMN, and the pharmacokinetics of a large NAD+ dose are still debated. The 100 mg in a MitoPrime vial is a research quantity, not a validated clinical protocol. For the broader picture, our NAD and peptides explainer covers why the two get confused.

MOTS-c (10 mg): the mitochondrial-derived peptide

MOTS-c is the genuine peptide of the group, a 16-amino-acid chain encoded within the mitochondrial 12S rRNA gene. It behaves less like a structural peptide and more like a hormone that reports on mitochondrial stress.

Its research record is the strongest of the three. In the original 2015 Cell Metabolism paper, MOTS-c activated AMPK, improved insulin sensitivity in diet-induced obese mice, and reduced age-related insulin resistance in older animals [2]. A 2021 Nature Communications study then showed that MOTS-c is induced by exercise and that treating mice, including animals started late in life, boosted running capacity and physical performance across young, middle-aged, and old groups [3]. Exercise raised skeletal-muscle MOTS-c roughly 12-fold in that work.

The ceiling on all of this is the same ceiling every mitochondrial peptide hits: the outcome data is rodent data. Circulating MOTS-c is detectable in humans and declines with age, but no completed human trial of administered MOTS-c has read out. Our full MOTS-c research guide goes deeper on dosing figures and the metabolic literature.

5-Amino-1MQ (10 mg): the NNMT inhibitor that isn't a peptide

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of NNMT. Calling it a peptide is wrong, though nearly every vendor does. It matters because a small molecule behaves differently from a peptide in dosing, stability, and how it is studied.

The interest traces to a 2014 Nature paper showing that knocking down NNMT in fat and liver protected mice against diet-induced obesity, glucose intolerance, and fatty liver, partly by shifting adipose NAD+ and SAM levels [4]. That put NNMT on the map as a metabolic target. In 2018, a Biochemical Pharmacology study reported that membrane-permeable NNMT inhibitors given to obese mice cut white fat mass and body weight and shrank adipocytes [5]. 5-Amino-1MQ is the most talked-about compound in that class.

So the fat-loss buzz around this ingredient rests on a real mechanism and real animal data. What it does not yet have is a controlled human trial. Our 5-Amino-1MQ guide walks through dosage figures, side-effect reports, and why the "peptide" label sticks despite the chemistry.

Potential benefits studied for the blend

Because no one has studied MitoPrime as a single product, its claimed benefits are inherited from the individual components. Here is where each claim actually stands.

Read that list as a set of research directions, not promises. The blend sits at the front edge of metabolic research, which is exactly why the marketing runs ahead of the evidence.

MitoPrime dosage: reading the 120 mg label

A MitoPrime vial states its split on the label: 100 mg NAD+ / 10 mg MOTS-c / 10 mg 5-Amino-1MQ. That is the total content of the dry vial, not a per-dose amount. How a researcher divides it depends entirely on reconstitution.

The workflow mirrors any lyophilized compound. The powder is dissolved in bacteriostatic water, and the volume of water sets the concentration. Draw a fraction of that solution and you get a fraction of each of the three ingredients in the same fixed ratio. You cannot dose the components independently in a pre-mixed blend, which is the main trade-off versus buying them separately.

Community protocols shared on forums like r/USPeptides tend to run MOTS-c in the low single-digit milligram range per dose and 5-Amino-1MQ higher over time, but these are anecdotes, not guidance, and the fixed blend ratio limits how far you can tune them. Treat any number you see online as a research log entry from a stranger, not a dose to copy.

Safety and side effects

There is no safety file for MitoPrime as a combined product, so the risk picture is assembled from the parts, and it is thin for all three in humans.

NAD+ infusions are associated with flushing, nausea, and chest tightness when pushed too fast, effects tied to rate more than dose. MOTS-c has little human safety data of any kind. 5-Amino-1MQ, as an NNMT inhibitor, alters a pathway involved in NAD+ and methylation balance, and its long-term effects in people are simply unstudied. Anyone with a hormone-sensitive condition, anyone pregnant or nursing, and anyone on prescription metabolic or diabetes medication sits outside what the research can speak to at all.

The blanket point holds: these compounds are sold for laboratory research only, none is an approved drug, and none has an established human dose.

The MitoPrime name problem: peptide blend vs. ergothioneine

Search "MitoPrime" and you will hit two completely different products, and most articles never mention it. This is the single biggest source of confusion around the name.

MitoPrime® (capital, trademarked) is a branded form of L-ergothioneine, an antioxidant amino acid sold by NNB Nutrition and used in capsules from brands like Xymogen. It has nothing to do with NAD+, MOTS-c, or 5-Amino-1MQ. It is a single ingredient, taken orally, marketed for antioxidant and longevity support.

MitoPrime (the peptide blend) is the NAD+/MOTS-c/5-Amino-1MQ research vial this guide covers, sold by research-chemical vendors as an injectable metabolic stack.

Same name, unrelated chemistry, different aisle. If a product page talks about ergothioneine, capsules, or "the longevity vitamin," you are looking at the supplement. If it lists a 120 mg vial with three metabolic compounds, that is the blend. Checking the ingredient list settles it in seconds.

How MitoPrime fits among metabolic blends

Pre-mixed metabolic vials are having a moment, and MitoPrime is one entry in a crowded shelf. Its identity is the NAD+-centric angle: most fat-loss stacks lean on GLP-1 compounds or growth-hormone peptides, while this one is built around the NAD+ salvage pathway and mitochondrial signaling.

The convenience of a fixed blend is also its limitation. You get three compounds in one reconstitution, but you cannot adjust the ratio, and you inherit the evidence gaps of all three at once. Researchers who want control often prefer the components separately. For the wider landscape, see our roundups of peptides studied for fat loss, longevity peptides, and popular peptide stacks.

Frequently asked questions

Where can you buy MitoPrime?

MitoPrime is stocked by online research-chemical suppliers that carry pre-mixed metabolic blends, usually listed as "MitoPrime," "NAD+/MOTS-c/5-Amino-1MQ blend," or "metabolic blend." Availability shifts often, and not every supplier stocks the three-component version. Our vendors directory lists research suppliers and manufacturers that may supply it, with community ratings, COA access, testing standards, and shipping options so you can compare before you order. Everything listed is sold for laboratory research use only.

Can you take NAD+ and 5-Amino-1MQ together?

In this blend they are already combined, and the pairing has a mechanistic rationale: NAD+ supplies the coenzyme, while 5-Amino-1MQ blocks the NNMT enzyme that would otherwise drain NAD+ precursors [4]. That said, the combination has not been tested for safety or effect in a human trial, so "can" here means chemically formulated together, not clinically validated.

Does 5-Amino-1MQ help with weight loss?

In animal studies, yes. NNMT inhibition reduced fat mass and body weight in obese mice [4][5]. There is no completed human weight-loss trial of 5-Amino-1MQ, so the effect in people remains unproven despite heavy marketing.

Is MOTS-c good for weight loss?

MOTS-c improved insulin sensitivity and reduced obesity in diet-induced obese mice by activating AMPK [2]. Like the rest of this blend, the fat-loss evidence is preclinical, and human outcome data does not yet exist.

Who should avoid 5-Amino-1MQ?

Anyone pregnant or nursing, anyone with a hormone-sensitive condition, and anyone on prescription diabetes or metabolic drugs falls outside what the research covers. Because it is an unstudied compound in humans, cautious researchers treat it as experimental across the board.

What is the best peptide for mitochondria?

MOTS-c is the peptide most directly tied to mitochondrial function, since it is encoded in mitochondrial DNA and signals mitochondrial stress [2][3]. SS-31 (elamipretine) is another compound studied for mitochondrial support. "Best" is not established, because head-to-head human data does not exist.

Is MitoPrime the same as the ergothioneine supplement?

No. The trademarked MitoPrime® supplement is L-ergothioneine, an oral antioxidant with no relation to this blend. The MitoPrime peptide vial is the NAD+/MOTS-c/5-Amino-1MQ research product. Check the ingredient list to tell them apart.

The bottom line

MitoPrime is a NAD+/MOTS-c/5-Amino-1MQ research blend built on a tidy idea: supply NAD+, stop the body from wasting it, and switch on the pathways that spend it. Each component has real preclinical support, and MOTS-c in particular has a solid animal record. What none of them has, alone or blended, is a completed human trial, so the blend belongs firmly in the research-and-hypothesis column rather than the proven-protocol one. Sold for laboratory use only, it is not an approved drug and has no established human dose.

Disclaimer

This article is for educational and informational purposes only and describes research findings. It is not medical advice, and the compounds discussed are intended for laboratory research use only. Consult a qualified healthcare professional before making any health decisions.

References